Literature DB >> 15560993

Use of the Alfieri edge-to-edge technique to eliminate left ventricular outflow tract obstruction caused by mitral systolic anterior motion.

A Marc Gillinov1, Nicholas G Smedira, Takahiro Shiota.   

Abstract

A 68-year-old woman with concentric left ventricular hypertrophy, prosthetic valve endocarditis with aortic root abscess, and sepsis had aortic root replacement with an aortic allograft. On weaning from cardiopulmonary bypass, she had hemodynamic instability caused by systolic anterior motion of the mitral valve, which resulted in a left ventricular outflow tract obstruction; the peak pressure gradient across the left ventricular outflow tract was 130 mm Hg, and there was moderately severe (3+) mitral regurgitation. After reinstitution of cardiopulmonary bypass, a central Alfieri edge-to-edge stitch was placed between the anterior and posterior leaflets of the mitral valve. This reduced the gradient across the left ventricular outflow tract to 10 mm Hg and eliminated the mitral regurgitation, which enabled successful separation from cardiopulmonary bypass.

Entities:  

Mesh:

Year:  2004        PMID: 15560993     DOI: 10.1016/j.athoracsur.2004.03.089

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  3 in total

1.  Transaortic edge-to-edge mitral valve repair and left ventricular myectomy.

Authors:  Yasushi Tsutsumi; Satoshi Numata; Hiroyuki Seo; Hirokazu Ohashi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-08-01

2.  Intraoperative evaluation of transmitral pressure gradients after edge-to-edge mitral valve repair.

Authors:  Jan N Hilberath; Holger K Eltzschig; Stanton K Shernan; Andrea H Worthington; Sary F Aranki; Martina Nowak-Machen
Journal:  PLoS One       Date:  2013-09-02       Impact factor: 3.240

3.  Will the Mitral Clip become the invasive treatment of choice for hypertrophic obstructive cardiomyopathy?

Authors:  Mohamad Alkhouli
Journal:  Postepy Kardiol Interwencyjnej       Date:  2014-09-11       Impact factor: 1.426

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.